...
首页> 外文期刊>Molecular pharmacology. >Role of protein kinase Czeta and its adaptor protein p62 in voltage-gated potassium channel modulation in pulmonary arteries.
【24h】

Role of protein kinase Czeta and its adaptor protein p62 in voltage-gated potassium channel modulation in pulmonary arteries.

机译:蛋白激酶Czeta及其衔接蛋白p62在肺动脉电压门控钾通道调节中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Voltage-gated potassium (K(V)) channels play an essential role in regulating pulmonary artery function, and they underpin the phenomenon of hypoxic pulmonary vasoconstriction. Pulmonary hypertension is characterized by inappropriate vasoconstriction, vascular remodeling, and dysfunctional K(V) channels. In the current study, we aimed to elucidate the role of PKCzeta and its adaptor protein p62 in the modulation of K(V) channels. We report that the thromboxane A(2) analog 9,11-dideoxy-11alpha,9alpha-epoxymethano-prostaglandin F(2alpha) methyl acetate (U46619) inhibited K(V) currents in isolated mice pulmonary artery myocytes and the K(V) current carried by human cloned K(V)1.5 channels expressed in Ltk(-) cells. Using protein kinase C (PKC)zeta(-/-) and p62(-/-) mice, we demonstrate that these two proteins are involved in the K(V) channel inhibition. PKCzeta coimmunoprecipitated with K(V)1.5, and this interaction was markedly reduced in p62(-/-) mice. Pulmonary arteries from PKCzeta(-/-) mice also showed a diminished [Ca(2+)](i) and contractile response, whereas genetic inactivation of p62(-/-) resulted in an absent [Ca(2+)](i) response, but it preserved contractile response to U46619. These data demonstrate that PKCzeta and its adaptor protein p62 play a key role in the modulation of K(V) channel function in pulmonary arteries. These observations identify PKCzeta and/or p62 as potential therapeutic targets for the treatment of pulmonary hypertension.
机译:电压门控钾(K(V))通道在调节肺动脉功能中起重要作用,并且它们是低氧性肺血管收缩现象的基础。肺动脉高压的特征是不适当的血管收缩,血管重塑和功能异常的K(V)通道。在当前的研究中,我们旨在阐明PKCzeta及其衔接蛋白p62在调节K(V)通道中的作用。我们报告血栓烷A(2)类似物9,11-dideoxy-11alpha,9alpha-epoxymethano-前列腺素F(2alpha)乙酸甲酯(U46619)抑制了离体小鼠肺动脉心肌细胞中的K(V)电流和K(V)在Ltk(-)细胞中表达的人类克隆的K(V)1.5通道所携带的电流使用蛋白激酶C(PKC)zeta(-/-)和p62(-/-)小鼠,我们证明这两种蛋白参与K(V)通道抑制。 PKCzeta与K(V)1.5共免疫沉淀,并且在p62(-/-)小鼠中这种相互作用明显减少。从PKCzeta(-/-)小鼠的肺动脉也显示减少[Ca(2 +)](i)和收缩反应,而p62(-/-)的遗传失活导致[Ca(2 +)]( i)响应,但保留了对U46619的收缩响应。这些数据证明PKCzeta及其衔接蛋白p62在肺动脉K(V)通道功能的调节中起关键作用。这些观察结果确定PKCzeta和/或p62是治疗肺动脉高压的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号